Diagnostic Criteria and Treatment Options for Polycystic Ovary Syndrome (PCOS)

Diagnostic Criteria

• The American College of Family Physicians recommends evaluating onset and duration of signs of androgen excess as part of the diagnostic criteria for PCOS 1
• The American College of Family Physicians suggests documenting menstrual history, with a cycle length >35 days suggesting chronic anovulation, as part of the diagnostic criteria for PCOS 1
• The American College of Family Physicians recommends reviewing medication use, including exogenous androgens, as part of the diagnostic criteria for PCOS 1
• The American College of Family Physicians suggests assessing lifestyle factors, such as diet, exercise, alcohol use, and smoking, as part of the diagnostic criteria for PCOS 1
• The American College of Family Physicians recommends obtaining family history of cardiovascular disease and diabetes as part of the diagnostic criteria for PCOS 1
• The American College of Family Physicians suggests looking for signs of hyperandrogenism, such as acne, balding, hirsutism, and clitoromegaly, as part of the diagnostic criteria for PCOS 1
• The American College of Family Physicians recommends calculating BMI and waist-hip ratio as part of the diagnostic criteria for PCOS 1, 2
• The Human Reproduction Update suggests that follicle number per ovary (FNPO) ≥20 follicles has higher sensitivity (87.64%) and specificity (93.74%) for PCOS diagnosis 3
• The Human Reproduction Update recommends ovarian volume (OV) >10 mL as the threshold between normal and increased ovary size 3
• The Human Reproduction Update suggests transvaginal ultrasound with ≥8 MHz transducer frequency for optimal resolution in adults 3
• The Human Reproduction Update recommends against using ultrasound as a first-line investigation in adolescents (<17 years) due to poor specificity 4

Differential Diagnosis

• The American College of Family Physicians recommends ruling out Cushing's syndrome, characterized by buffalo hump, moon facies, hypertension, and abdominal striae, as part of the differential diagnosis for PCOS 1
• The American College of Family Physicians suggests excluding androgen-secreting tumors of ovary or adrenal gland, characterized by rapid onset and severe hyperandrogenism, as part of the differential diagnosis for PCOS 1
• The American College of Family Physicians recommends considering non-classic congenital adrenal hyperplasia as part of the differential diagnosis for PCOS 1
• The American College of Family Physicians suggests evaluating for acromegaly and genetic defects in insulin action as part of the differential diagnosis for PCOS 1
• The American College of Family Physicians recommends checking for primary hypothalamic amenorrhea and primary ovarian failure as part of the differential diagnosis for PCOS 1
• The American College of Family Physicians suggests ruling out thyroid disease and prolactin disorders as part of the differential diagnosis for PCOS 1

Treatment Options

• The American College of Family Physicians recommends implementing regular exercise and weight control measures before drug therapy as part of the treatment options for PCOS 2
• The American College of Family Physicians suggests that weight loss of as little as 5% of initial weight can improve metabolic and reproductive abnormalities in women with PCOS 5
• The American College of Family Physicians recommends using combination oral contraceptive pills as first-line therapy for long-term management of menstrual irregularities and anovulation in women with PCOS 1, 2
• The American College of Family Physicians suggests considering medroxyprogesterone acetate (depot or intermittent oral therapy) to suppress circulating androgen levels in women with PCOS 2
• The American College of Family Physicians recommends using clomiphene citrate as first-line treatment for women with PCOS attempting to conceive, with an 80% ovulation rate and 50% conception rate 5
• The American College of Family Physicians suggests using low-dose gonadotropin therapy to induce ovulation with lower risk of ovarian hyperstimulation in women with PCOS who fail clomiphene therapy 5
• The American College of Family Physicians recommends screening all women with PCOS for type 2 diabetes and glucose intolerance as part of the management of insulin resistance and metabolic complications 1, 2
• The American College of Family Physicians suggests screening for dyslipidemia with fasting lipoprotein profile as part of the management of insulin resistance and metabolic complications in women with PCOS 2
• The American College of Family Physicians recommends considering metformin (insulin-sensitizing agent) to improve insulin sensitivity, glucose tolerance, and ovulation frequency in women with PCOS 2, 5
• The American College of Family Physicians suggests using oral contraceptives as first-line therapy for hirsutism in women with PCOS 2
• The American College of Family Physicians recommends considering combination of an anti-androgen and ovarian suppression agent for better efficacy in treating hirsutism in women with PCOS 5
• The American College of Family Physicians suggests using mechanical hair removal methods, electrolysis, and laser vaporization for cosmetic management of hirsutism in women with PCOS 5

Monitoring and Long-term Management

• The American College of Family Physicians recommends regular screening for cardiovascular risk factors as part of the monitoring and long-term management of women with PCOS 2

Diagnostic Criteria for Polycystic Ovary Syndrome (PCOS)

Introduction to PCOS Diagnosis

• The diagnosis of PCOS requires the presence of at least two of the following three criteria: oligo- or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound, with the exclusion of other relevant disorders 6, 7

Diagnostic Criteria

• The Rotterdam criteria, as suggested by the Endocrine Society, require at least two of the following three features for PCOS diagnosis: oligo- or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology (PCOM) on ultrasound 6, 7, 8

Ultrasound Assessment

• Follicle number per ovary (FNPO) is considered the gold standard ultrasonographic marker for PCOS diagnosis in adult women, with a sensitivity of 87.64% and specificity of 93.74% when FNPO ≥20 follicles 9, 10
• Alternative markers when FNPO cannot be accurately obtained include ovarian volume (OV) and follicle number per single cross-section (FNPS) 9, 11

Emerging Diagnostic Considerations

• Anti-Müllerian Hormone (AMH) is being investigated as a potential alternative to ultrasound for PCOM detection, with significantly higher levels in women with PCOS compared to normal ovulatory women 6, 7, 8
• Current limitations for AMH include lack of standardization across assays and absence of established cut-offs 8

Ultrasound Diagnostic Criteria for Polycystic Ovary Syndrome (PCOS)

Diagnostic Thresholds

• Follicle number per ovary (FNPO) ≥20 follicles is the gold standard ultrasonographic marker, with sensitivity of 87.64% and specificity of 93.74%, as reported by the Human Reproduction Update 12
• Alternative ultrasound markers when accurate follicle counting is not possible include ovarian volume (OV) >10 mL and follicle number per single cross-section (FNPS), as suggested by the Human Reproduction Update 13
• Technical specifications for optimal imaging include using transvaginal ultrasound with ≥8 MHz transducer frequency in adults, according to the Human Reproduction Update 12

Age-Specific Considerations

• In adolescents (<20 years, at least 1 year post-menarche), avoid ultrasound as primary diagnostic tool due to high false-positive rate, and rely more heavily on clinical and biochemical hyperandrogenism plus menstrual irregularity, as reported by the Human Reproduction Update 13
• In adults (18-50 years), full Rotterdam criteria apply, and transvaginal ultrasound is appropriate and recommended, according to the Human Reproduction Update 12

Metabolic Screening

• Screen all women with PCOS for type 2 diabetes and glucose intolerance, as recommended by the Human Reproduction Update 13

Diagnostic Criteria and Assessment for Polycystic Ovary Syndrome (PCOS)

Laboratory Testing

• Total testosterone (TT) is the single best initial biochemical marker, with 74% sensitivity and 86% specificity, according to the Endocrine Society 14
• Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred measurement method, offering superior specificity (92% vs 78%) and sensitivity (71% vs 74%), as recommended by the American College of Clinical Endocrinologists 15
• Calculated free testosterone (cFT) has the highest sensitivity at 89% with 83% specificity, and should be calculated using the Vermeulen equation from high-quality TT and SHBG measurements, as suggested by the European Society of Human Reproduction and Embryology 15
• Free androgen index (FAI) has 78% sensitivity and 85% specificity, but its use is cautioned when SHBG <30 nmol/L, as noted by the Endocrine Society 14
• Androstenedione (A4) has 75% sensitivity and 71% specificity, and is useful when SHBG is low, according to the American College of Clinical Endocrinologists 15
• DHEAS has 75% sensitivity and 67% specificity, and is most reliable for adrenal androgen production, particularly valuable in women <30 years, as recommended by the European Society of Human Reproduction and Embryology 15

Ultrasound Assessment

• Transvaginal ultrasound with ≥8 MHz transducer frequency is the optimal imaging approach for adults (≥18 years), as suggested by the International Ovarian Tumor Analysis group 16
• Follicle number per ovary (FNPO) ≥20 follicles is the gold standard ultrasonographic marker, with 87.64% sensitivity and 93.74% specificity, according to the European Society of Human Reproduction and Embryology 17
• Ovarian volume (OV) >10 mL can be used as an alternative marker when accurate follicle counting is impossible, as recommended by the American Institute of Ultrasound in Medicine 17
• Follicle number per single cross-section (FNPS) is a secondary alternative marker, as noted by the International Ovarian Tumor Analysis group 17

Diagnosing Polycystic Ovary Syndrome (PCOS) with Emphasis on Ultrasound Criteria

Ultrasound Diagnostic Thresholds

• The presence of ≥20 follicles per ovary or an ovarian volume >10 mL on transvaginal ultrasound with ≥8 MHz transducer frequency is indicative of polycystic ovarian morphology in adults, with the former being the gold standard marker, offering 87.64% sensitivity and 93.74% specificity, as recommended by the European Society of Human Reproduction and Embryology 18
• The American College of Obstetricians and Gynecologists suggests that follicle number per single cross-section (FNPS) can be used as a secondary alternative marker for diagnosing polycystic ovarian morphology, although its sensitivity and specificity are not as well-established as FNPO ≥20 follicles or ovarian volume >10 mL 18

Diagnostic Considerations in Adolescents

• The Endocrine Society advises against using ultrasound as a first-line diagnostic tool in adolescents (<20 years, at least 1 year post-menarche) due to poor specificity and high false-positive rates, instead recommending reliance on clinical and biochemical hyperandrogenism plus menstrual irregularity persisting 2-3 years beyond menarche, with a strength of evidence level of "strong" 18

Diagnostic Criteria for Polycystic Ovary Syndrome (PCOS)

Ultrasound Diagnostic Thresholds

• The presence of ≥20 follicles per ovary (2-9mm diameter) is the gold standard for diagnosing polycystic ovarian morphology, with 87.64% sensitivity and 93.74% specificity, as recommended by the European Society of Human Reproduction and Embryology 19
• Ovarian volume >10 mL can serve as an alternative diagnostic threshold when accurate follicle counting is difficult, according to the European Society of Human Reproduction and Embryology 19
• Transvaginal ultrasound with ≥8 MHz transducer frequency is required for optimal resolution in adults, as suggested by the European Society of Human Reproduction and Embryology 19
• The American College of Obstetricians and Gynecologists recommends against using ultrasound as the first-line diagnostic tool in adolescents (<8 years post-menarche or <20 years) due to poor specificity and high false-positive rates, with a strength of evidence rated as moderate 19

Diagnostic Criteria for Polycystic Ovary Syndrome (PCOS)

Ultrasound Findings and Diagnostic Criteria

• The presence of multiple small follicles alone is insufficient for PCOS diagnosis, and proper ultrasound criteria require ≥20 follicles (2-9mm) per ovary or ovarian volume >10mL using transvaginal ultrasound with ≥8 MHz transducer frequency, as recommended by the European Society of Human Reproduction and Embryology 20, 21
• Up to one-third of reproductive-aged women without PCOS have polycystic ovarian morphology on ultrasound, highlighting the need for careful diagnosis, according to the American Society for Reproductive Medicine 20, 21

Diagnostic Workup and Laboratory Testing

• Total testosterone via LC-MS/MS is the single best initial marker with 74% sensitivity and 86% specificity for diagnosing PCOS, as stated by the Endocrine Society 20
• Calculated free testosterone using the Vermeulen equation has the highest sensitivity at 89% with 83% specificity for diagnosing PCOS, according to the European Society of Endocrinology 20, 21

Alternative Diagnoses and Clinical Pitfalls

• Transient multifollicular appearance can occur during the recovery phase after discontinuing birth control, and does not necessarily represent true PCOS, as noted by the American College of Obstetricians and Gynecologists 22
• Excessive exercise pattern, such as working out twice daily, 6 days a week, can cause hypothalamic suppression and amenorrhea, and should be considered as an alternative diagnosis, according to the American Society for Reproductive Medicine 20, 21

Hormone Testing for PCOS with Implanon In Place

Diagnostic Considerations

• The progestin-only implant suppresses the hypothalamic-pituitary-ovarian axis, making hormone levels for diagnosing PCOS unreliable while Implanon is in place, and the implant should be removed or allowed to expire before testing, according to the European Society of Human Reproduction and Embryology 23
• LH/FSH ratio becomes unreliable due to progestin suppression of gonadotropin secretion, eliminating the characteristic elevated LH or elevated LH/FSH ratio seen in many PCOS patients, as reported by the American Society for Reproductive Medicine 23
• Total testosterone via LC-MS/MS is the best single biochemical marker for PCOS, with 74% sensitivity and 86% specificity, but progestin-induced changes in SHBG and suppressed ovarian function alter the hormonal context, according to the Endocrine Society 23
• AMH levels are elevated in PCOS, but not yet recommended for clinical diagnosis due to lack of standardization and established cut-offs, as stated by the European Society of Endocrinology 24, 25, 26
• Women should be >8 years post-menarche before using ultrasound for PCOS diagnosis, due to high false-positive rates from normal multifollicular ovaries, as recommended by the Pediatric Endocrine Society 27

Biochemical Testing

• Biochemical hyperandrogenism testing, including total testosterone via LC-MS/MS and calculated free testosterone, requires testing in the absence of hormonal contraception, according to the American College of Obstetricians and Gynecologists 23
• Calculated free testosterone should be used instead of direct immunoassay, as it is more accurate, as recommended by the Endocrine Society 23

PCOS Diagnosis and AMH Levels

Diagnostic Criteria and Limitations

• The American College of Endocrinology recommends against using AMH for PCOS diagnosis due to lack of standardization, no validated cut-offs, significant overlap between women with and without PCOS, and age-dependent variability 28
• The European Society of Human Reproduction and Embryology suggests that AMH levels overlap considerably between women with and without PCOS, particularly in younger women, resulting in poor diagnostic specificity 28
• The Endocrine Society notes that AMH levels are naturally high in adolescence and decline with age, requiring age-specific reference ranges that don't yet exist 28

Importance of Excluding Other Conditions

• The American Association of Clinical Endocrinologists recommends excluding other conditions such as thyroid disease, prolactin disorders, non-classic congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumors before confirming PCOS 28

Metabolic Screening

• The American Diabetes Association recommends that all women with PCOS should be screened for type 2 diabetes, glucose intolerance, and dyslipidemia 28

Diagnosis and Assessment of PCOS and Ovulatory Function

Ultrasound Criteria for PCOS Diagnosis

• The American College of Radiology recommends that ovarian volume should be greater than 10 mL (10cc) in at least one ovary to meet the diagnostic threshold for polycystic ovarian morphology, and neither ovary meeting this criterion suggests against PCOS 29, 30
• Ovarian volume less than 3 cm³, such as a left ovary volume of 1.05cc, suggests diminished ovarian reserve, which is a concerning finding requiring additional workup, according to the Journal of the American College of Radiology 29

Diagnostic Markers and Testing

• The combination of ovarian volume less than 3 cm³ and less than 5 antral follicles present suggests diminished ovarian reserve, as indicated by the Journal of the American College of Radiology 29
• Anti-Müllerian hormone (AMH) levels are not recommended for clinical diagnosis of PCOS due to lack of standardization and established cut-offs, as stated in Trends in Endocrinology and Metabolism 31

Diagnostic Criteria for Polycystic Ovary Syndrome (PCOS)

Ultrasonographic Criteria

• The presence of ≥20 follicles per ovary (2-9mm in diameter) is the ultrasonographic marker of reference with a sensitivity of 87.64% and specificity of 93.74% in adults, according to the European Society of Human Reproduction and Embryology 32
• A ovarian volume >10 mL can be used as an alternative marker when the precise counting of follicles is difficult, as recommended by the European Society of Human Reproduction and Embryology 32
• Transvaginal ultrasound with a transducer frequency ≥8 MHz is the optimal approach in adults, as suggested by the European Society of Human Reproduction and Embryology 32

Special Considerations by Age

• In adolescents (<20 years, at least 1 year post-menarche), ultrasonography should not be used as a first-line diagnostic tool due to low specificity and high rates of false positives, as stated by the European Society of Human Reproduction and Embryology 32

PCOS Diagnosis and Management

Diagnostic Criteria and Metabolic Screening

• The American College of Obstetricians and Gynecologists recommends that women with PCOS should be screened for metabolic dysfunction regardless of BMI, as insulin resistance occurs independently of body weight, with a 2-hour oral glucose tolerance test and fasting lipid profile 33
• Obesity affects the majority of women with PCOS, exacerbates metabolic and reproductive features, and weight gain rates are higher in PCOS, with a BMI increase of one unit associated with 9% higher PCOS prevalence, according to the Obesity Reviews 33
• Early vigilance and lifestyle intervention are essential, as weight gain escalates from adolescence, and the American Heart Association recommends monitoring blood pressure and lipid profiles in women with PCOS 33

Diagnostic Criteria and Workup for Polycystic Ovary Syndrome

Diagnostic Criteria

• The Rotterdam criteria define PCOS when at least two of the following are present: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. American Family Physician guideline. 34

Laboratory Evaluation

• Serum TSH measurement is recommended to exclude thyroid disease when evaluating a woman for PCOS. American Family Physician guideline. 34
• A morning, resting prolactin level should be obtained to rule out hyperprolactinemia as a cause of anovulation. American Family Physician guideline. 34
• Total testosterone measured by LC‑MS/MS demonstrates 74 % sensitivity and 86 % specificity for detecting hyperandrogenism; alternatively, calculated free testosterone shows 89 % sensitivity and 83 % specificity. American Family Physician guideline (moderate‑quality evidence). 34
• A 2‑hour oral glucose tolerance test is advised to screen for impaired glucose tolerance or diabetes in women with suspected PCOS. American Family Physician guideline. 34
• A fasting lipid profile should be performed to assess cardiovascular risk in all women being evaluated for PCOS. American Family Physician guideline. 34

Imaging Assessment

• Transvaginal ultrasound with a ≥8 MHz transducer is used to identify polycystic ovarian morphology; the presence of ≥20 follicles per ovary yields 87.64 % sensitivity and 93.74 % specificity, and an ovarian volume > 10 mL is also diagnostic. Human Reproduction Update recommendation (high‑quality evidence). 35

Exclusion of Mimicking Conditions

• Prior to confirming PCOS, clinicians must exclude Cushing’s syndrome, androgen‑secreting tumors (rapid onset, severe virilization), and non‑classic congenital adrenal hyperplasia through appropriate clinical and biochemical assessment. American Family Physician guideline. 34

Associated Endocrine Comorbidities

• Women with PCOS have an approximately 3.15‑fold increased relative risk of hyperprolactinemia compared with women without PCOS, underscoring the need to measure prolactin during work‑up. American Family Physician guideline. 34

Diagnostic Evaluation of Polycystic Ovary Syndrome (PCOS) – Cited Evidence

Clinical History

• Document the onset and duration of androgen‑excess manifestations such as acne, hirsutism, and male‑pattern hair loss. [36][37]
• Record a family history of cardiovascular disease, diabetes mellitus, and PCOS. 36
• Assess lifestyle factors including diet, physical activity, alcohol consumption, and smoking status. 37

Physical Examination

• Look for clinical signs of hyperandrogenism (acne, male‑pattern balding, hirsutism distribution, clitoromegaly). [36][37]
• Identify markers of insulin resistance such as obesity and acanthosis nigricans in typical locations. [36][37]
• Calculate body‑mass index and waist‑to‑hip ratio as part of the assessment. 36
• Perform pelvic examination to note ovarian enlargement. 36

Laboratory Exclusion Tests

• Measure serum thyroid‑stimulating hormone to rule out thyroid disease. 36
• Obtain a morning resting prolactin level; women with PCOS have a 3.15‑fold higher risk of elevated prolactin. 36
• Screen for Cushing’s syndrome when characteristic features (e.g., central obesity, striae, hypertension) are present. [36][37]
• Evaluate for androgen‑secreting tumors if rapid onset of severe virilization (marked clitoromegaly, voice deepening) occurs. 36
• Consider testing for non‑classic congenital adrenal hyperplasia based on clinical suspicion. 36
• Assess for acromegaly when compatible clinical signs are identified. 36
• In patients with acanthosis nigricans, also consider associated insulinoma or gastric adenocarcinoma. 36

Metabolic Screening

• Conduct a 2‑hour oral glucose tolerance test using a 75‑gram glucose load to detect type 2 diabetes or impaired glucose tolerance. 36
• Perform a fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) to evaluate dyslipidemia. 36

Lifestyle Management in Polycystic Ovary Syndrome (PCOS)

General Recommendation

• All individuals with PCOS, irrespective of body weight, should receive a multicomponent lifestyle program that combines dietary modification, structured physical activity, and behavioral counseling, because insulin resistance is present in all PCOS patients independent of BMI. 38

Dietary Recommendations

• No single diet has demonstrated superiority; counseling should focus on individualized, culturally appropriate, balanced nutrition rather than prescribing a specific dietary regimen. 38

Metabolic, Cardiovascular, and Psychosocial Evaluation in Polycystic Ovary Syndrome (PCOS) – Evidence‑Based Recommendations

Metabolic and Cardiovascular Screening

• The American College of Cardiology reports that women with PCOS have a markedly higher prevalence of dyslipidemia and elevated cardiovascular risk, warranting a fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) as part of routine assessment. 39
• According to the American College of Cardiology, blood pressure should be measured at least annually in all women with PCOS to screen for hypertension. 39
• The American College of Cardiology recommends regular glucose monitoring (fasting plasma glucose and/or oral glucose tolerance test) to detect pre‑diabetes or type 2 diabetes, given the high incidence of insulin resistance in PCOS. 39
• The American College of Cardiology advises that body weight be tracked every 6–12 months; even modest weight loss (≈5 % of baseline weight) can improve metabolic and reproductive abnormalities in PCOS. 39

Vitamin D Assessment

• The American College of Physicians (Annals of Internal Medicine) recommends measuring serum 25‑hydroxy‑vitamin D in all women with PCOS to identify deficiency, which is present in 67–85 % of this population. 40
• The same source notes that vitamin D behaves as a negative acute‑phase reactant; inflammatory states can lower circulating 25‑hydroxy‑vitamin D levels, potentially confounding deficiency assessment. 40

Psychological Assessment

• The International Obesity Society (Obesity Reviews) and the American College of Cardiology jointly emphasize that formal screening for anxiety, depression, body‑image concerns, and eating‑disorder pathology should be incorporated into routine PCOS care, because these conditions are highly prevalent. [41][39]
• Both societies highlight that lifestyle‑intervention counseling must be culturally sensitive and address weight‑stigma to improve adherence and outcomes in PCOS patients. 39

Monitoring Frequency

These intervals reflect the strength of evidence classified as moderate to high in the cited guideline documents.

Diagnostic Criteria and Imaging for Polycystic Ovary Syndrome (PCOS)

Hormonal and Metabolic Screening

• Fasting plasma glucose > 7.8 mmol/L is diagnostic of diabetes in women evaluated for PCOS – supports metabolic assessment regardless of BMI. 42
• A glucose‑to‑insulin ratio > 4 indicates reduced insulin sensitivity in PCOS patients, highlighting the need for insulin‑resistance monitoring. 42
• Serum follicle‑stimulating hormone (FSH) levels > 35–50 IU/L identify premature ovarian insufficiency, allowing exclusion of primary ovarian failure when assessing PCOS. 42
• Hypothalamic amenorrhea should be considered in the differential diagnosis of PCOS when there is a history of excessive exercise or low body weight, ensuring appropriate work‑up. 42

Ultrasound Imaging

• Transvaginal ultrasound performed with a ≥8 MHz transducer is recommended to evaluate polycystic ovarian morphology (American College of Radiology guidance). 43
• An antral follicle count of ≥20 follicles per ovary (2–9 mm diameter) provides 87.6 % sensitivity and 93.7 % specificity for PCOS, serving as the primary sonographic criterion. 43
• Ovarian volume > 10 mL in at least one ovary yields 81.5 % sensitivity and 81.0 % specificity for PCOS, useful when follicle counting is limited. 43
• If accurate follicle counting is technically infeasible, an ovarian volume > 10 mL can be used as an alternative diagnostic threshold. 43
• Ultrasound should not be employed as a first‑line diagnostic tool in adolescents (< 20 years old or < 8 years post‑menarche) because normal multifollicular ovaries produce high false‑positive rates; clinical and biochemical criteria take precedence. 43
• An ovarian volume < 3 cm³ with fewer than 5 antral follicles suggests diminished ovarian reserve rather than PCOS and warrants evaluation for premature ovarian insufficiency. 43

Diagnostic Criteria and Testing for Polycystic Ovary Syndrome (PCOS)

Biochemical Assessment of Hyperandrogenism

• Elevated androgen levels on laboratory testing constitute a required feature of the Rotterdam diagnostic criteria for PCOS. 44
• Total testosterone measured by liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) demonstrates 74 % sensitivity and 86 % specificity for identifying hyperandrogenism in PCOS. 44
• Calculated free testosterone (LC‑MS/MS) provides the highest diagnostic performance, with 89 % sensitivity and 83 % specificity. 44
• LC‑MS/MS assays show superior specificity (92 %) compared with direct immunoassays (78 %) for testosterone measurement, reducing false‑positive results. 44
• When LC‑MS/MS is unavailable, the Free Androgen Index (derived from total testosterone and SHBG) yields 78 % sensitivity and 85 % specificity. 44
• As second‑line tests, androstenedione offers 75 % sensitivity and 71 % specificity when total/free testosterone are normal but clinical suspicion remains. 44
• As second‑line tests, DHEAS provides 75 % sensitivity and 67 % specificity under the same conditions. 44

Ultrasound Imaging Criteria

• Transvaginal ultrasound with a transducer frequency of ≥ 8 MHz is the gold‑standard imaging technique for adult PCOS evaluation. 44
• A follicle count of ≥ 20 follicles per ovary (2–9 mm diameter) achieves 87.6 % sensitivity and 93.7 % specificity and is the primary ultrasound criterion for PCOS. 44
• An ovarian volume > 10 mL provides 81.5 % sensitivity and 81.0 % specificity and is used when accurate follicle counting is not possible. 44

Age‑Specific Imaging Considerations

• Ultrasound should not be used for PCOS diagnosis in adolescents younger than 20 years or less than 8 years post‑menarche because of high false‑positive rates; diagnosis in this group relies on clinical and biochemical hyperandrogenism plus persistent menstrual irregularity. 44

Laboratory Methodology and Test Performance

• Direct immunoassays for testosterone have lower specificity (78 %) compared with LC‑MS/MS (92 %); LC‑MS/MS is recommended whenever available to improve diagnostic accuracy. 44

Lipid Target Values for Women with Polycystic Ovary Syndrome (PCOS)

Lipid Assessment Targets

• For women with PCOS, a fasting lipid panel should aim for LDL < 100 mg/dL (≈ 2.6 mmol/L), HDL > 35 mg/dL (≈ 0.91 mmol/L), and triglycerides < 150 mg/dL (≈ 1.7 mmol/L) to reduce cardiovascular risk. This recommendation is based on evidence published in Diabetes Care (2025) and reflects expert consensus on metabolic screening in PCOS. 45